Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)

被引：0

作者：

Warren, Richard B. ^{[1
]}

de Bruin-Weller, Marjolein ^{[2
]}

Tsianakas, Athanasios ^{[3
]}

Khemis, Abdallah ^{[4
]}

Szepietowski, Jacek C. ^{[5
]}

Hong, H. Chih-Ho ^{[6
]}

Armengol, Clara ^{[7
]}

Falques, Meritxell ^{[7
]}

Agell, Helena ^{[7
]}

Massana, Eric ^{[7
]}

Gil, Esther Garcia ^{[7
]}

Weidinger, Stephan ^{[8
]}

机构：

[1] Univ Manchester, Northern Care Alliance NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, England

[2] Univ Med Ctr Utrecht, Utrecht, Netherlands

[3] Fachklin Bad Bentheim, Bad Bentheim, Germany

[4] Polyclin St George Grp Kantys, Dermatol, Nice, France

[5] Med Univ, Wroclaw, Poland

[6] Univ British Columbia, Vancouver, BC, Canada

[7] Almirall SA, Barcelona, Spain

[8] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷

关键词：

lebrikizumab; topical corticosteroids; investigator global assessment; eczema area and severity index; pruritis numeric rating scale;

D O I：

10.1093/bjd/ljae266.005

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

619

引用

页数：2

共 17 条

[1] Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
Katoh, Norito
Tanaka, Akio
Takahashi, Hidetoshi
Shimizu, Ryosuke
Kataoka, Yoko
Torisu-Itakura, Hitoe
Morisaki, Yoji
Igawa, Ken
CURRENT MEDICAL RESEARCH AND OPINION, 2025, 41 (01) : 1 - 12
[2] Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Simpson, Eric L.
Flohr, Carsten
Eichenfield, Lawrence F.
Bieber, Thomas
Sofen, Howard
Taieb, Alain
Owen, Ryan
Putnam, Wendy
Castro, Marcela
DeBusk, Kendra
Lin, Chin-Yu
Voulgari, Athina
Yen, Karl
Omachi, Theodore A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) : 863 - +
[3] Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Guttman-Yassky, Emma
Silverberg, Jonathan I.
Nemoto, Osamu
Forman, Seth B.
Wilke, August
Prescilla, Randy
de la Pena, Amparo
Nunes, Fabio P.
Janes, Jonathan
Gamalo, Margaret
Donley, David
Paik, Jim
DeLozier, Amy M.
Nickoloff, Brian J.
Simpson, Eric L.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (04) : 913 - +
[4] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide A.
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan D.
Pierce, Evangeline
Elmaraghy, Hany
Pillai, Sreekumar
Dawson, Zach
Chen, Sherry
Armengol, Clara
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
[5] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[6] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Carrascosa, Jose Manuel
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan, I
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[7] Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials
Mendes-Bastos, Pedro
Ladizinski, Barry
Guttman-Yassky, Emma
Jiang, Ping
Liu, John
Prajapati, Vimal H.
Simpson, Eric L.
Vigna, Namita
Teixeira, Henrique D.
Barbarot, Sebastien
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 784 - 791
[8] The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis
Soung, Jennifer
Laquer, Vivian
Merola, Joseph F.
Moore, Angela
Elmaraghy, Hany
Hu, Chaoran
Piruzeli, Maria Lucia Buziqui
Pierce, Evangeline
Gil, Esther Garcia
Jarell, Abel D.
DERMATOLOGY AND THERAPY, 2024, 14 (08) : 2181 - 2193
[9] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Paller, Amy S.
Flohr, Carsten
Eichenfield, Lawrence F. F.
Irvine, Alan D. D.
Weisman, Jamie
Soung, Jennifer
Correia, Ana Pinto
Natalie, Chitra R. R.
Capriles, Claudia Rodriguez
Pierce, Evangeline
Reifeis, Sarah
Lima, Renata Gontijo
Tubau, Clara Armengol
Laquer, Vivian
Weidinger, Stephan
DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
[10] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Amy S. Paller
Carsten Flohr
Lawrence F. Eichenfield
Alan D. Irvine
Jamie Weisman
Jennifer Soung
Ana Pinto Correia
Chitra R. Natalie
Claudia Rodriguez Capriles
Evangeline Pierce
Sarah Reifeis
Renata Gontijo Lima
Clara Armengol Tubau
Vivian Laquer
Stephan Weidinger
Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534

← 1 2 →